Functional constipation induces bladder overactivity associated with upregulations of Htr2 and Trpv2 pathways

Nao Iguchi1, Alonso Carrasco2,3, Alison X Xie1

  • 1Division of Urology, Department of Surgery, University of Colorado Denver School of Medicine, 12700 E 19th Avenue, Aurora, CO, 80045, USA.

Scientific Reports
|January 14, 2021
PubMed

Insights

Constipation in children can cause bladder problems like urinary frequency and overactivity. This is linked to increased serotonin receptor activity in the bladder, contributing to bladder and bowel dysfunction (BBD).

Area of Science:

  • Pediatric Urology
  • Gastroenterology
  • Neuroscience

Background:

  • Bladder and bowel dysfunction (BBD) is a common pediatric condition involving lower urinary tract symptoms (LUTS) and bowel issues like constipation.
  • BBD is a risk factor for long-term urinary tract problems, but its underlying mechanisms and treatments are not well understood.

Purpose of the Study:

  • To investigate the impact of constipation on lower urinary tract function in a juvenile animal model.
  • To explore the role of serotonin receptors in constipation-induced bladder changes.

Main Methods:

  • A juvenile murine model was used to induce functional constipation for four days.
  • Awake cystometry evaluated LUTS, and in vitro bladder strip physiology assessed detrusor function.
  • Serotonin receptor expression (Htr2a, Htr2c) and response to serotonin were analyzed.

Main Results:

  • Constipation led to LUTS, including urinary frequency and detrusor overactivity.
  • Bladder strips showed increased spontaneous contractions, with enhanced response to serotonin.
  • Serotonin receptors Htr2a and Htr2c were upregulated in bladders of constipated mice.

Conclusions:

  • Constipation induces detrusor overactivity in juvenile mice.
  • Increased excitatory serotonin receptor activation in the bladder contributes to BBD development.
  • Findings suggest a link between constipation, serotonin signaling, and pediatric bladder dysfunction.

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
487
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
635
The Micturition Reflex01:26

The Micturition Reflex

Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
1.8K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
433
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
674
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
407